Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy

20Citations
Citations of this article
43Readers
Mendeley users who have this article in their library.

Abstract

There is no standard of care for older patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive therapy, and prognosis with currently recommended low-intensity therapies (decitabine, azacitidine, and low-dose cytarabine [LDAC]) remains poor. One promising strategy is to combine low-intensity treatments with novel agents. Gemtuzumab ozogamicin, tipifarnib, and barasertib have been investigated in phase 2/3 or 3 trials combined with LDAC, and phase 3 trials are currently investigating sapacitabine plus decitabine, and volasertib plus LDAC in AML. This review discusses current treatment recommendations and the development of combination therapies for older patients unfit for intensive therapy.

Cite

CITATION STYLE

APA

Erba, H. P. (2015). Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leukemia Research, 39(2), 183–191. https://doi.org/10.1016/j.leukres.2014.11.027

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free